Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property

Principal signs R&D deal with University of Oxford

PTEC · Price

Executive Summary

  • Principal Technologies Inc. entered into a research and development agreement with the University of Oxford to develop and test its thermal sensor technology for medical applications, including cancer diagnosis and treatment.
  • The company announced the divestiture of its majority stake (reducing ownership from 80% to 20%) in its Austrian subsidiary, E&E CRO Consulting GmbH, to the subsidiary's management for nominal value.
  • The divestiture is subject to corporate and regulatory approvals, including acceptance by the TSX Venture Exchange.

Key Details

  • R&D Agreement: Principal Technologies has entered into an agreement with the University of Oxford to develop and test the thermal sensor, which is the subject of the company's long-term license with the university.
  • Applications: The development focuses on at least seven proposed medical applications of the Oxford proprietary heat-sensing technology, with a main focus on cancer diagnosis and treatment.
  • Divestiture Structure: Principal Technologies is reducing its stake in E&E CRO Consulting GmbH from 80% to 20%.
  • Transaction Consideration: The remaining shares are being sold to the management of E&E CRO for their nominal value.
  • Rationale: The decision follows a review of operations and an increasing focus on the company's own research and development activities.
  • Subsidiary Role: E&E CRO advises healthcare companies on how to efficiently conduct clinical studies.
  • Conditions Precedent: Completion of the E&E CRO disposition is subject to the receipt of all requisite corporate and regulatory approvals, including acceptance of the TSX Venture Exchange.

Notable Quotes

  • "We are excited about the development phase of the thermal sensor," said Principal chief executive officer Jerry Trent. "There are at least seven proposed medical applications of the Oxford proprietary heat-sensing technology and the successful development of these applications has become a main focus of our organization going forward."
Read the original news release →

More from Principal Technologies Inc